<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145936</url>
  </required_header>
  <id_info>
    <org_study_id>1541 - Fatty Acid Pilot</org_study_id>
    <nct_id>NCT02145936</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation</brief_title>
  <official_title>Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to determine the effect of habituation to diets with&#xD;
      different types of dietary fat (stearic, palmitic and oleic) on selected Cardiovascular&#xD;
      Disease (CVD) risk indicators with an emphasis on inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vegetable oils high in the specific fatty acids of interest - stearic (found in cocoa butter,&#xD;
      meats), palmitic (found in meats, dairy and some plant oils) and stearic acid's metabolic&#xD;
      product, oleic (found in olive and corn oil) - will be used to displace each other in a&#xD;
      standardized diet and fed to mildly hypercholesterolemic postmenopausal women using a&#xD;
      randomized-controlled crossover design. A critical issue remains unresolved - the relative&#xD;
      comparability among . The findings from this research study will enable us to understand the&#xD;
      mechanism and potential health effect of different types of fats. Each of the diet phases&#xD;
      will be 5 weeks in length with a 2-4 week break between phases. All food and drink will be&#xD;
      provided to study volunteers. Blood pressure and body weight will be monitored once per week&#xD;
      and adjustments made, if necessary, to maintain a stable weight. During the 5th week of each&#xD;
      diet phase, volunteers will come to the center on 3 consecutive days to provide fasting blood&#xD;
      samples and a non-fasting blood sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>15-weeks</time_frame>
    <description>interleukine (IL)-6, tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, C-reactive protein (CRP), soluble forms of intercellular adhesion protein (slCAM)-1, vascular cell adhesion protein (sVCAM)-1, sE-selectin, sP-selectin and li0poprotein associated phospholipase A2 (LpPLA2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lymphocyte proliferation and ex vivo cytokine secretion</measure>
    <time_frame>15 weeks</time_frame>
    <description>IL-1, IL-6, TNF-alpha, and prostaglandin E2 (PGE2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma lipids and lipoproteins</measure>
    <time_frame>15 weeks</time_frame>
    <description>TC, HDL, LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>desaturase activity</measure>
    <time_frame>15 weeks</time_frame>
    <description>8CD, D6D, D5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>15 weeks</time_frame>
    <description>glucose, insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coagulation biomarkers</measure>
    <time_frame>15 weeks</time_frame>
    <description>prothrombin time (PT), partial thromboplastin time (PTT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>oleic acid diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with meals enriched in oleic acid (18:1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>palmitic acid diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with meals enriched in palmitic acid (18:0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stearic acid diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with meals enriched in stearic acid (18:0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diet</intervention_name>
    <description>Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.</description>
    <arm_group_label>oleic acid diet</arm_group_label>
    <arm_group_label>palmitic acid diet</arm_group_label>
    <arm_group_label>stearic acid diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The inclusion and exclusion criteria for both studies A and B are identical.&#xD;
&#xD;
          -  Postmenopausal women (menopause defined by complete natural cessation of menses for&#xD;
             &gt;12 months or a bilateral oophorectomy).&#xD;
&#xD;
          -  Age &gt;50 to &lt; 85 years&#xD;
&#xD;
          -  BMI &gt;20 to &lt;35 kg/m2&#xD;
&#xD;
          -  LDL-cholesterol &gt;100 mg/dL&#xD;
&#xD;
          -  CRP &lt;10 ug/dL&#xD;
&#xD;
          -  Normal fasting plasma glucose levels (&lt;120 mg/dL)&#xD;
&#xD;
          -  Not taking medication known to affect lipid metabolism:&#xD;
&#xD;
        HMG-CoA reductase inhibitors (statins)&#xD;
&#xD;
          -  Bile Acid Sequestrants (Cholestyramine, Colestipol, Colesevelam, etc.)&#xD;
&#xD;
          -  Cholesterol Absorption Inhibitors (Ezetimibe [Zetia])&#xD;
&#xD;
          -  Nicotinic Acid Agents (Niacin, Niacor, Slo-Niacin, etc)&#xD;
&#xD;
          -  Fibrates (Gemfibrozil, Clofibrate, Ciprofibrate, Fenofibrate [Tricor], etc)&#xD;
&#xD;
          -  Probucol&#xD;
&#xD;
          -  Anticoagulants (Coumadin, Heparin, Plavix, etc)&#xD;
&#xD;
          -  Hormone therapy medications containing estrogen&#xD;
&#xD;
          -  Acetylsalicylic acid containing medications, aspirin&#xD;
&#xD;
          -  Diphenylhydantoin&#xD;
&#xD;
          -  Supplements containing fatty acids (Fish Oil, Flaxseed, etc.) and any other compounds&#xD;
             that affect lipid metabolism (red yeast rice, etc.) for at least 3 months prior to&#xD;
             participation in the study&#xD;
&#xD;
          -  Anabolic steroids&#xD;
&#xD;
          -  Hydrocortisone&#xD;
&#xD;
               -  Normal kidney function as assessed by serum creatinine and blood urea nitrogen&#xD;
&#xD;
               -  Normal liver function as assessed by serum glutamic pyruvic transaminase, serum&#xD;
                  glutamic oxaloacetic transaminase and alkaline phosphatase&#xD;
&#xD;
               -  Normal thyroid function as assessed by serum TSH&#xD;
&#xD;
               -  Normal gastrointestinal function&#xD;
&#xD;
               -  Normotensive on or off medication&#xD;
&#xD;
               -  Non-smoker for at least 2 years&#xD;
&#xD;
               -  Alcohol intake &lt; 7 drinks per week, and willingness to abstain from consuming&#xD;
                  alcohol while participating in the study.&#xD;
&#xD;
               -  Consistent physical activity&#xD;
&#xD;
               -  Willingness to follow protocol as detailed in the Institutional Review Board&#xD;
                  (IRB) approved consent form.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Women who have had a double mastectomy&#xD;
&#xD;
          -  Age &lt; 50 and &gt; 85 years&#xD;
&#xD;
          -  BMI &lt; 20 and &gt; 35 kg/m2&#xD;
&#xD;
          -  LDL-cholesterol &lt;100 mg/dL&#xD;
&#xD;
          -  CRP &gt; 10 ug/dL&#xD;
&#xD;
          -  Abnormal fasting plasma glucose levels &gt;120 mg/dL&#xD;
&#xD;
          -  Use of medications known to affect lipid metabolism:&#xD;
&#xD;
               -  HMG-CoA reductase inhibitors (statins)&#xD;
&#xD;
               -  Bile Acid Sequestrants (Cholestyramine, Colestipol, Colesevelam, etc.)&#xD;
&#xD;
               -  Cholesterol Absorption Inhibitors (Ezetimibe [Zetia])&#xD;
&#xD;
               -  Nicotinic Acid Agents (Niacin, Niacor, Slo-Niacin, etc)&#xD;
&#xD;
               -  Fibrates (Gemfibrozil, Clofibrate, Ciprofibrate, Fenofibrate [Tricor], etc)&#xD;
&#xD;
               -  Anticoagulants (Coumadin, Heparin, Plavix, etc)&#xD;
&#xD;
               -  Hormone therapy medications containing estrogen&#xD;
&#xD;
               -  Probucol&#xD;
&#xD;
               -  Acetylsalicylic acid containing medications, aspirin&#xD;
&#xD;
               -  Diphenylhydantoin&#xD;
&#xD;
               -  Supplements containing fatty acids (Fish Oil, Flaxseed, etc.) and any other&#xD;
                  compounds that affect lipid metabolism (red yeast rice, etc.) in the last 3&#xD;
                  months prior to participation in the study&#xD;
&#xD;
               -  Anabolic steroids and hydrocortisone&#xD;
&#xD;
          -  Renal or kidney disease, as defined by a history of chronic kidney disease or by&#xD;
             glomerular filtration rate of &lt; 60 ml.min/1.73 m2 calculated from screening blood&#xD;
             tests.&#xD;
&#xD;
          -  Hypothyroidism or hyperthyroidism, as defined as screening TSH outside of normal&#xD;
             ranges (&lt;0.4 or &gt;4.5), unless controlled with medication for at least 6 months&#xD;
&#xD;
          -  Gastrointestinal disease&#xD;
&#xD;
          -  Uncontrolled hypertension or high BP reading at the discretion of the study physician&#xD;
             or nurse&#xD;
&#xD;
          -  Established cardiovascular disease as defined by history of myocardial infarction,&#xD;
             stroke, heart failure, coronary artery bypass graft, stenosis &gt;50%, angina and&#xD;
             peripheral arterial disease)&#xD;
&#xD;
          -  Anemia, as defined by screening haemoglobin &lt;11.7g/dL.&#xD;
&#xD;
          -  Liver disease, as defined by a history of chronic hepatitis B or C, cholestatic or&#xD;
             cirrhotic liver disease, nonalcoholic fatty liver disease, elevations of SGPT or SGOT&#xD;
             greater than 1.5 times the upper limit of normal at screening, bilirubin greater than&#xD;
             2 mg/dL (in the absence of benign causes of elevated bilirubin such as Gilbert's&#xD;
             syndrome) at screening, or albumin below the lower limit of normal.&#xD;
&#xD;
          -  Type I and II diabetes&#xD;
&#xD;
          -  Any non-steroidal anti-inflammatory drugs (NSAID) or antihistamine use by subject for&#xD;
             72 hours prior to blood draws&#xD;
&#xD;
          -  Smoking or use of nicotine-containing products within the past 2 years&#xD;
&#xD;
          -  Alcohol intake &gt; 7 drinks per week or unwillingness to abstain from consuming alcohol&#xD;
             while participating in the study&#xD;
&#xD;
          -  Unwillingness to maintain body weight during participation in the study&#xD;
&#xD;
          -  Unwillingness to adhere to diet and study protocol&#xD;
&#xD;
          -  Weight gain or loss of more than 15 lb within 6 months prior to enrollment&#xD;
&#xD;
          -  Vegetarians and those with food allergies or aversions&#xD;
&#xD;
          -  Non-English speaking subjects&#xD;
&#xD;
          -  No Social Security number&#xD;
&#xD;
          -  Women who have a history of difficulty with blood draws&#xD;
&#xD;
          -  Blood donation within the past 8 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice H Lichtenstein, D.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University/HNRCA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer Human Nutrition Research Center on Aging</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

